- Home
- THAR
THAR
Tharimmune Inc.
as 11-15-2024 4:00pm EST
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | BRIDGEWATER |
| Market Cap: | 2.8M | IPO Year: | 2022 |
| Target Price: | N/A | AVG Volume (30 days): | 3.3M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -11.95 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.83 - $79.50 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Tharimmune Inc. (THAR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Appajosyula Sireesh | THAR | Chief Operating Officer | Nov 13 '24 | Buy | $2.02 | 5,000 | $10,096.00 | 10,758 | |
| MILBY RANDY | THAR | CEO | Oct 8 '24 | Buy | $2.09 | 2,500 | $5,221.04 | 11,934 | |
| Appajosyula Sireesh | THAR | Chief Operating Officer | Oct 8 '24 | Buy | $1.93 | 5,000 | $9,650.00 | 10,758 |
Latest Tharimmune Inc. News
THAR Breaking Stock News: Dive into THAR Ticker-Specific Updates for Smart Investing
ACCESSWIRE
5 days ago
Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics
ACCESSWIRE
14 days ago
Tharimmune Announces Upcoming Conference Presentations
ACCESSWIRE
19 days ago
Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis
ACCESSWIRE
21 days ago
Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting
ACCESSWIRE
24 days ago
Tharimmune Announces Upcoming Conference Presentations
ACCESSWIRE
2 months ago
Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company
ACCESSWIRE
2 months ago
Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab
ACCESSWIRE
4 months ago
Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board
Compare THAR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "THAR Tharimmune Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.